Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17194353 | 0.82 | ADORA1 (0.50) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL3421633 | 0.81 | ALDH1A1 (0.62) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL17194372 | 0.81 | ADORA1 (0.54) | MAPTADORA1KDM4EP2RX3MKNK1 | |
| SCHEMBL17194176 | 0.80 | ADORA1 (0.55) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL17194311 | 0.80 | ADORA1 (0.55) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL20922384 | 0.80 | ADORA1 (0.55) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL2643671 | 0.80 | MAPT (0.73) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL2643572 | 0.79 | MEN1 (0.56) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL2643570 | 0.79 | MEN1 (0.53) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL2644838 | 0.78 | MEN1 (0.55) | MAPTMEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131890-B1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | PASTEUR INSTITUT KOREA (KR) | 2019-04-24 | — | — | EP | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| WO-2015158908-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | MAPT 2197/4885MEN1 4484/4885KMT2A 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.